Upcoming Financial Results Announcement by Compass Pathways
Compass Pathways plc (Nasdaq: CMPS), a pioneering biotechnology company focused on transforming mental health care, has announced plans to release its financial results for the third quarter. The report, which will cover developments through September 30, is expected to be shared with the public on October 31.
Conference Call Details for Investors
There will be a conference call at 8:00 am ET (12:00 pm UK) on the day of the announcement. Interested participants are encouraged to register in advance to receive the necessary local or toll-free phone numbers and a personal pin for the call.
Accessing the Call
Participants looking to join the call can find registration options on the Compass Pathways website. The company strives to make it easy for stakeholders to stay informed and engaged with its progress.
Live Webcast of the Financial Results
In addition to the conference call, a live webcast will also be available for those looking to follow the discussion online. This will be accessible through the Compass Pathways website, where it will be stored for a period of 30 days post-event for viewers who might not be able to attend live.
Investment Information Availability
For those who are interested in the ongoing developments within Compass Pathways, additional information can be found in the investors section of their official website. The company actively uses various communication channels to keep the public up-to-date, including investor presentations and updates about innovative treatments.
Understanding Compass Pathways’ Mission
With a mission to tackle the limitations of current mental health treatments, Compass Pathways is dedicated to improving the lives of individuals facing mental health issues. Their innovative approach involves the use of a proprietary formulation of synthetic psilocybin—known as COMP360—paired with psychological support.
Significant Clinical Developments
The company is actively conducting clinical trials to assess the effectiveness of its treatments. Notably, the phase 3 clinical program for COMP360 in treatment-resistant depression (TRD) stands out as the most extensive and rigorous of its kind. Preliminary phase 2b studies have shown promising results, demonstrating considerable improvements in depressive symptoms.
Support for PTSD and Anorexia Nervosa
Compass Pathways is expanding its research boundaries by also conducting studies targeting post-traumatic stress disorder (PTSD) and anorexia nervosa. These initiatives reflect their commitment to finding evidence-based solutions for various mental health challenges.
Company Overview
Compass Pathways is headquartered in London, with additional offices located in New York and San Francisco. The company's vision encompasses a comprehensive approach towards achieving mental wellbeing, demonstrating a strong commitment to innovation within the mental health sector.
Keeping Investors Informed
To facilitate ongoing communication with stakeholders, Compass Pathways emphasizes the importance of transparency. Their various digital platforms serve as a means to share significant updates regarding clinical trials, market developments, and financial performance.
Engagement Through Social Media and Online Platforms
Investors are encouraged to explore the company's social media presence and dedicated investor relations website. These platforms provide timely updates and insights that can significantly impact ongoing investment decisions.
Frequently Asked Questions
When will Compass Pathways announce its Q3 financial results?
Compass Pathways will announce its third quarter financial results on October 31.
How can investors participate in the conference call?
Investors can register in advance through the Compass Pathways website to receive the call details.
Is there a webcast available for the financial results?
Yes, a live webcast will be available on the Compass Pathways website and will be archived for 30 days.
What is COMP360?
COMP360 is a proprietary formulation of synthetic psilocybin developed by Compass Pathways for treatment-resistant depression.
Where is Compass Pathways headquartered?
Compass Pathways is headquartered in London, with offices in New York and San Francisco.
